# Polaryx Therapeutics, Inc.: overview PLYX · Nasdaq · CIK 2075320 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/plyx.md) · [Financials](/companies/plyx/financials.md) · [Filings](/companies/plyx/filings.md) · [Insiders](/companies/plyx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.11)](/filings/0001213900-26-056973.md) | [(0.02)](/filings/0001213900-26-089118.md) | [(0.05)](/filings/0001213900-26-056973.md) | [(0.03)](/filings/0001213900-26-089118.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | | Revenue | $ | not reported | not reported | | Gross margin | % | not reported | not reported | | Operating margin | % | not reported | not reported | | Net margin | % | not reported | not reported | | Diluted EPS | $ per share | [(0.89)](/filings/0001213900-26-033064.md) | [(0.20)](/filings/0001213900-26-033064.md) | | Free cash flow | $ | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/plyx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $4.4m | 1,657,872 | | Reduced −516 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $455.1k | 170,998 | | Added +325 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $279.5k | 105,072 | | Added +516 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $154.6k | 58,104 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $109.1k | 41,012 | | Unchanged | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $83.6k | 31,441 | | New +31,441 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $74.4k | 27,987 | | Unchanged | | [Allworth Financial LP](/funds/1555170.md) | 2026-06-30 | $20.6k | 7,727 | | New +7,727 | | [Vanguard Global Advisers, LLC](/funds/1811242.md) | 2026-06-30 | $16.8k | 6,318 | | Unchanged | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $8.0k | 3,002 | | Added +1,221 | ## Recent filings [All 35 filings](/companies/plyx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-14 | 19:59 ET | [8-K](/filings/0001213900-26-099416.md) | 5.07 Shareholder vote results | 0001213900-26-099416 | | 2026-09-01 | 16:30 ET | [8-K](/filings/0001213900-26-096235.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-096235 | | 2026-08-13 | 16:15 ET | [10-Q](/filings/0001213900-26-089118.md) | Quarterly report, period 2026-06-30 | 0001213900-26-089118 | | 2026-07-28 | 17:00 ET | [DEF 14A](/filings/0001213900-26-082339.md) | Proxy statement, period 2026-09-10 | 0001213900-26-082339 | | 2026-07-21 | 16:30 ET | [8-K](/filings/0001213900-26-080041.md) | 5.02 Departure or appointment of officers or directors | 0001213900-26-080041 | | 2026-07-17 | 08:00 ET | [8-K](/filings/0001213900-26-078912.md) | 5.08 Item not in the standard list; 8.01 Other events | 0001213900-26-078912 | | 2026-05-28 | 16:31 ET | [8-K](/filings/0001213900-26-062155.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-062155 | | 2026-05-15 | 20:01 ET | [10-Q](/filings/0001213900-26-056973.md) | Quarterly report, period 2026-03-31 | 0001213900-26-056973 | | 2026-03-24 | 17:48 ET | [10-K](/filings/0001213900-26-033064.md) | Annual report, period 2025-12-31 | 0001213900-26-033064 | | 2026-02-05 | 16:05 ET | [SCHEDULE 13D](/filings/0001213900-26-012759.md) | Ownership report, active investor | 0001213900-26-012759 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-033064.md), filed Mar 24, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 2075320 - Tickers: PLYX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: WY - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.